Navigation Links
Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial

TORONTO, June 18 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI), a company developing products for the treatment of sepsis, today announced that findings demonstrating the Toraymyxin(TM) cartridge, a blood purification device that absorbs endotoxin from the bloodstream, when added to conventional therapy, significantly improved hemodynamics and organ dysfunction and reduced 28-day mortality in patients with severe sepsis and septic shock. The article entitled "Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock: The EUPHAS Randomized Controlled Trial," was published in the Journal of the American Medical Association (JAMA). Spectral has exclusive rights to Toraymyxin(TM) in the United States and plans to initiate a trial in the U.S. in the latter half of 2009.

"The degree of reduction in mortality demonstrated by Toraymyxin(TM) in the EUPHAS trial is an unprecedented result for sepsis therapies and indicates that this product has the potential to fulfill an unmet need for the approximately 100,000 patients that develop severe sepsis or septic shock in the U.S. each year," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "Our Endotoxin Activity Assay (EAA(TM)) has the ability to identify patients who could benefit from this therapy and monitor its effect. Together, this diagnostic and therapeutic have the potential to provide a more effective treatment for patients with severe sepsis and septic shock caused by endotoxemia."

The objective of this study was to determine whether Toraymyxin(TM), when added to conventional medical therapy, improves clinical outcomes and mortality compared with conventional therapy alone, in a targeted patient population with severe sepsis and/or septic shock associated with intra-abdominal infections.

    -   28 day mortality was 32% (11/34 patients) in the Toraymyxin(TM) group
        and 53% (16/30 patients) in the conventional therapy group.
    -   Mean Arterial Pressure (MAP) increased (76 to 84 mm Hg;
        P = 0.001) in the Toraymyxin(TM) group but not in the
        conventional therapy group (MAP, 74 to 77 mm Hg; P =
    -   Vasopressor requirement decreased (inotropic score, 29.9 to 6.8; P
        (less than) 0.001) at 72 hours in the Toraymyxin(TM) group but not in
        the conventional therapy group (inotropic score, 28.6 to 22.4; P
        = 0.14).
    -   Sequential Organ Failure Assessment scores improved in the Toraymyxin
        (TM) group but not in the conventional therapy group (change in SOFA,
        -3.4 vs -0.1; P (less than) 0.001).

    The abstract and full text of the article is available online at and appears in JAMA. 2009; Vol. 301 # 23, 2445-2452.

    About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral will seek FDA approval for Toraymyxin(TM) and intends to commercialize the product together with EAA(TM). Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.

SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral announces first quarter 2009 results
2. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
3. Spectral announces 2008 financial results
4. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
5. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
6. Spectral announces third quarter 2008 results
7. Spectral to bring anti-sepsis therapy to the U.S. market
8. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
9. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral and Toray expand collaboration to include new geographic territories
Post Your Comments:
(Date:11/30/2015)... N.Y. , Nov. 30, 2015  Culprits ... by assistant chemistry professor Jan Halámek, is taking ...   --> ...   --> ... at UAlbany have discovered a straightforward concept for ...
(Date:11/30/2015)... Md. , Nov. 30, 2015 ... development company committed to the fostering and monetization ... the current and prospective initiatives designed to create ... Chief Executive Officer of Spherix. "Based on published ... future licensees exceeds $50 billion and Spherix will ...
(Date:11/30/2015)... DIEGO , Nov. 30, 2015 Human ... that the company has acquired Cypher Genomics, Inc., a ... robust human genomic interpretation software solutions. The ... will join HLI including Cypher CEO and Co-founder, Ashley ... of HLI,s Pediatric Business.  Financial details of the deal ...
(Date:11/30/2015)... Nov. 30, 2015  Aytu BioScience, Inc. (OTCQB: AYTU), ... related conditions, will present at two upcoming investor conferences. ... interactive real-time virtual conference, to be held December 3, ... to be held December 2 nd & 3 ... and streamed live via webcast. Josh ...
Breaking Biology Technology:
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
Breaking Biology News(10 mins):